An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines

All available vaccines for coronavirus disease 2019 (COVID-19) express or deliver the full-length SARS-CoV-2 spike (S) protein. We show that this antigen is not optimal, consistent with observations that the vast majority of the neutralizing response to the virus is focused on the S-protein recepto...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yan Guo, Wenhui He, Huihui Mou, Lizhou Zhang, Jing Chang, Shoujiao Peng, Amrita Ojha, Rubens Tavora, Mark S. Parcells, Guangxiang Luo, Wenhui Li, Guocai Zhong, Hyeryun Choe, Michael Farzan, Brian D. Quinlan
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2021
Materias:	Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/6183610d6fb446c1b899921bc6de5b56
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6183610d6fb446c1b899921bc6de5b56
record_format	dspace
spelling	oai:doaj.org-article:6183610d6fb446c1b899921bc6de5b562021-11-03T21:15:04ZAn Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines2150-751110.1128/mBio.00930-21https://doaj.org/article/6183610d6fb446c1b899921bc6de5b562021-06-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00930-21https://doaj.org/toc/2150-7511 All available vaccines for coronavirus disease 2019 (COVID-19) express or deliver the full-length SARS-CoV-2 spike (S) protein. We show that this antigen is not optimal, consistent with observations that the vast majority of the neutralizing response to the virus is focused on the S-protein receptor-binding domain (RBD).Yan GuoWenhui HeHuihui MouLizhou ZhangJing ChangShoujiao PengAmrita OjhaRubens TavoraMark S. ParcellsGuangxiang LuoWenhui LiGuocai ZhongHyeryun ChoeMichael FarzanBrian D. QuinlanAmerican Society for MicrobiologyarticleMicrobiologyQR1-502ENmBio, Vol 12, Iss 3 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Microbiology QR1-502
spellingShingle	Microbiology QR1-502 Yan Guo Wenhui He Huihui Mou Lizhou Zhang Jing Chang Shoujiao Peng Amrita Ojha Rubens Tavora Mark S. Parcells Guangxiang Luo Wenhui Li Guocai Zhong Hyeryun Choe Michael Farzan Brian D. Quinlan An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
description	All available vaccines for coronavirus disease 2019 (COVID-19) express or deliver the full-length SARS-CoV-2 spike (S) protein. We show that this antigen is not optimal, consistent with observations that the vast majority of the neutralizing response to the virus is focused on the S-protein receptor-binding domain (RBD).
format	article
author	Yan Guo Wenhui He Huihui Mou Lizhou Zhang Jing Chang Shoujiao Peng Amrita Ojha Rubens Tavora Mark S. Parcells Guangxiang Luo Wenhui Li Guocai Zhong Hyeryun Choe Michael Farzan Brian D. Quinlan
author_facet	Yan Guo Wenhui He Huihui Mou Lizhou Zhang Jing Chang Shoujiao Peng Amrita Ojha Rubens Tavora Mark S. Parcells Guangxiang Luo Wenhui Li Guocai Zhong Hyeryun Choe Michael Farzan Brian D. Quinlan
author_sort	Yan Guo
title	An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
title_short	An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
title_full	An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
title_fullStr	An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
title_full_unstemmed	An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
title_sort	engineered receptor-binding domain improves the immunogenicity of multivalent sars-cov-2 vaccines
publisher	American Society for Microbiology
publishDate	2021
url	https://doaj.org/article/6183610d6fb446c1b899921bc6de5b56
work_keys_str_mv	AT yanguo anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT wenhuihe anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT huihuimou anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT lizhouzhang anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT jingchang anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT shoujiaopeng anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT amritaojha anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT rubenstavora anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT marksparcells anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT guangxiangluo anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT wenhuili anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT guocaizhong anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT hyeryunchoe anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT michaelfarzan anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT briandquinlan anengineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT yanguo engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT wenhuihe engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT huihuimou engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT lizhouzhang engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT jingchang engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT shoujiaopeng engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT amritaojha engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT rubenstavora engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT marksparcells engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT guangxiangluo engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT wenhuili engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT guocaizhong engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT hyeryunchoe engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT michaelfarzan engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines AT briandquinlan engineeredreceptorbindingdomainimprovestheimmunogenicityofmultivalentsarscov2vaccines
_version_	1718445398996025344

An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines

Ejemplares similares